# Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

> **NCT02243202** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 335 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Phentermine
- **DRUG:** Matching Placebo to Canagliflozin
- **DRUG:** Matching Placebo to Phentermine

## Key facts

- **NCT ID:** NCT02243202
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243202, "Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02243202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*